Asset
Uridine triacetate
Repligen Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00060515 | phase1 | terminated | — | — | Repligen Corporation | RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease |
FDA applications (0)
This company has no applications containing this asset.